Scientific deep-dive

Tirzepatide Microdosing: Sub-Therapeutic Dose Evidence

No trial has tested tirzepatide below the 2.5 mg starting dose, so microdosing is off-label. What each SURMOUNT-1 dose step produced, harm-reduction advice for people already doing it, and what to ask your prescriber.

By Eli Marsden · Founding Editor
Editorially reviewed & fact-checked against primary sources · How we verify contentLast reviewed
9 min read·6 citations

Tirzepatide microdosing — using doses below the FDA-approved 2.5 mg starting dose — has become a popular strategy in patient communities, mostly for cost reasons (compounded vials are priced per mg) and side effect tolerance. The SURMOUNT-1 trial[1] tested 5, 10, and 15 mg maintenance doses with a 2.5 mg starter; no formal trial has tested anything below 2.5 mg. This article walks through what the published dose-response curve actually shows, why any dose below the FDA-approved starting dose is off-label, and the conversation patients should have with their prescriber rather than self-microdosing in isolation.

What “microdosing” actually means in this context

In tirzepatide patient communities, “microdosing” typically refers to one of three things:

  • Sub-2.5 mg doses (e.g., 1 mg, 1.25 mg, or 1.5 mg weekly) — below the FDA-approved 2.5 mg starting dose
  • Staying on 2.5 mg indefinitely rather than escalating to the 5/10/15 mg maintenance doses — this is technically a label-allowed starter dose but not a maintenance dose per the prescribing information
  • Splitting the weekly dose into two smaller injections (e.g., half-dose Mondays and half-dose Thursdays) — pharmacologically distinct from microdosing but often grouped under the same patient term

None of these is FDA-approved as a maintenance regimen for Zepbound or Mounjaro[4][5]. The first and third are completely off-label; the second is on the label as a starter dose only.

The published SURMOUNT-1 dose-response data

SURMOUNT-1[1] was the obesity registration trial for tirzepatide and tested three maintenance doses against placebo over 72 weeks in 2,539 adults with BMI ≥30 (or ≥27 with comorbidity). Mean weight loss at 72 weeks:

  • Placebo — −3.1%
  • Tirzepatide 5 mg — −16.0%
  • Tirzepatide 10 mg — −19.5%
  • Tirzepatide 15 mg — −20.9%

Magnitude comparison

SURMOUNT-1 dose-response — mean body-weight reduction at 72 weeks across the three tested maintenance doses vs placebo. The 2.5 mg starter step has no published 72-week maintenance endpoint, and no formal trial has tested any tirzepatide dose below 2.5 mg — the microdosing region is uncharacterized.[1]

  • Microdose region (sub-2.5 mg weekly)0.0 % TBWL
    no formal trial arm — efficacy is unknown
  • 2.5 mg — SURMOUNT-1 starter step only (4 weeks)2.5 % weight loss
    trial run-in approximation; no maintenance endpoint published
  • Placebo (SURMOUNT-1, 72 weeks)3.1 % TBWL
  • Tirzepatide 5 mg — SURMOUNT-1 maintenance (72 wk)16.0 % TBWL
  • Tirzepatide 10 mg — SURMOUNT-1 maintenance (72 wk)19.5 % TBWL
  • Tirzepatide 15 mg — SURMOUNT-1 maintenance (72 wk)20.9 % TBWL
SURMOUNT-1 dose-response — mean body-weight reduction at 72 weeks across the three tested maintenance doses vs placebo. The 2.5 mg starter step has no published 72-week maintenance endpoint, and no formal trial has tested any tirzepatide dose below 2.5 mg — the microdosing region is uncharacterized.

Notice the shape of the curve: the jump from placebo to 5 mg is large (16 percentage points), the jump from 5 mg to 10 mg is moderate (3.5 points), and the jump from 10 mg to 15 mg is small (1.4 points). The dose-response is steep at the low end and flattens at the high end. This is the scientific basis for the microdosing argument: if 5 mg produces 16% weight loss, what does 2.5 mg or 1.25 mg do?

What we know (and don't know) about doses below 5 mg

The 2.5 mg dose was used in SURMOUNT-1 as a 4-week starter dose only, not as a maintenance dose. There is no published 72-week efficacy result for tirzepatide 2.5 mg as a maintenance dose, and there is no published trial of any dose below 2.5 mg. Inferences from the SURMOUNT-1 dose-response curve and from the SURPASS diabetes trials [2] suggest that:

  • 2.5 mg as a starter produces a small amount of weight loss (~2-3% over 4 weeks in the trial run-in periods)
  • 2.5 mg as a sustained dose would probably produce more weight loss than placebo but substantially less than 5 mg — extrapolating the dose-response curve
  • 1-1.25 mg doses — completely uncharacterized in the published literature. We have no trial data on what they actually do

In the Phase 1 study, the pharmacokinetics appeared dose-proportional over the dose range tested, which ran from single doses of 0.25 mg up to 15 mg[3], so a 1.25 mg dose would be expected to produce roughly half the steady-state plasma concentration of a 2.5 mg dose. Whether that produces meaningful weight loss is an empirical question that has not been answered.

Why patients microdose anyway

Three motivations dominate:

  1. Cost. Compounded tirzepatide is priced per mg in many telehealth pharmacies. A 1.25 mg weekly regimen costs roughly half as much as a 2.5 mg regimen and a quarter as much as 5 mg. For patients paying out of pocket, the cost difference is large. At clinics that charge one price at every dose, a lower dose saves nothing; our list of flat-price GLP-1 providers shows which ones price that way. At Temi, which shows each partner pharmacy's price before you order, a 28-day tirzepatide vial order in California runs from $143.99 at the 2 mg starting dose to $198.99 at 16.6 mg a week, including its $39 prescription service.
  2. Side effect tolerance. Some patients who cannot tolerate the standard 2.5 mg starter dose due to nausea, vomiting, or fatigue find that a fractional dose is tolerable. For these patients, microdosing is the difference between staying on tirzepatide and stopping entirely.
  3. Avoiding the “rebound” from full discontinuation. Patients who reach their goal weight on a higher dose but want to maintain on a lower dose to avoid the weight regain documented in the SURMOUNT-4 trial sometimes microdose as a maintenance strategy.

The risks and unknowns

  • Efficacy is unknown at doses below 2.5 mg. Patients may believe they are getting a benefit that's not actually there (or that's smaller than expected).
  • Compounded tirzepatide quality varies. A microdose from a high-quality PCAB-accredited compounder is a different thing from a microdose from a gray-market source. See our PCAB accreditation investigation for our vetting framework.
  • Splitting weekly doses changes the pharmacokinetics. Tirzepatide's once-weekly dosing is designed for the ~5-day half-life. Splitting into two injections per week shifts the peak-to-trough ratio in ways that have not been formally studied.
  • Off-label dosing puts the prescriber at higher risk. A prescriber writing for a non-labeled dose is taking on additional clinical and medicolegal exposure compared with a labeled dose. Some legitimate prescribers will not do it.
  • Insurance and brand-name programs do not cover microdosing. Wegovy NovoCare, Zepbound LillyDirect, and most insurance formularies dispense in standard label doses only. Microdosing is essentially a compounded-pharmacy-only phenomenon.

The conversation to have with your prescriber

If you are considering microdosing tirzepatide — for cost, for tolerance, or for maintenance after goal weight — bring it up explicitly with your prescriber rather than doing it in isolation. Useful framing for that conversation:

  • State the reason. Cost, tolerance, or maintenance? Each reason maps to different alternative strategies.
  • Ask about staying on a lower labeled dose. For some patients, the right answer is to stay on Zepbound 5 mg long-term rather than escalating to 15 mg, or to de-escalate from 15 mg back to 10 mg or 5 mg as a maintenance strategy. These are still labeled doses but at the lower end.
  • Ask about Foundayo (oral orforglipron) as an alternative. The new oral GLP-1 has a different titration schedule and more granular dose levels. For some cost-sensitive patients it's the better answer than microdosing tirzepatide.
  • Document your weight and symptoms so you and your prescriber can tell whether the microdose is actually doing anything.
  • Use a PCAB-accredited compounder if you go this route. The compounded supply chain is the weakest link.

What this article is NOT

This article does not endorse or recommend tirzepatide microdosing. There is no published efficacy or safety data at doses below 2.5 mg, and any dose below the FDA-approved starting dose is off-label[6]. The article exists to answer the question patients are actually searching for, summarize the trial data that does exist, and redirect the decision back to a clinical conversation with a qualified prescriber.

Bottom line

  • SURMOUNT-1 tested 5, 10, and 15 mg as maintenance doses and 2.5 mg as a 4-week starter. No formal trial has tested doses below 2.5 mg.
  • The dose-response curve is steep at the low end and flattens at the high end — so a 5 mg dose is much closer to 15 mg in efficacy than the dose ratio would suggest.
  • Doses below 2.5 mg are off-label, and their weight-loss effect has not been tested in trials. The Phase 1 study found dose-proportional pharmacokinetics, so concentration should scale with dose, but the weight-loss effect at fractional doses is unknown.
  • Patient motivations for microdosing are real (cost, tolerance, maintenance), and there are sometimes better on-label alternatives (lower labeled dose, switching to Foundayo, switching to compounded semaglutide).
  • If you choose to microdose, do it with your prescriber, a PCAB-accredited compounder, and documented monitoring — not in isolation.

Off-label dosing decisions should be made with a qualified prescriber who knows your medical history. Tirzepatide is FDA-approved as Zepbound and Mounjaro at the labeled doses only; any dose below 2.5 mg is unstudied, and any compounded supply should come from a PCAB-accredited pharmacy.

Further reading

Our reviews

Providers that offer tirzepatide

Telehealth providers we’ve reviewed. Each opens our full, independent review.

We may earn a commission from featured partners. Learn more

See the full ranking →

Frequently Asked Questions

Tirzepatide microdosing is the practice of using doses below the FDA-approved 2.5/5/7.5/10/12.5/15mg titration schedule — typically 0.5mg to 2mg weekly. It is most often discussed in the context of compounded vials where the prescriber has flexibility to dose by volume. There are no FDA-approved microdosing protocols and no published RCTs of tirzepatide microdosing for weight loss.
There are no published randomized controlled trials of tirzepatide microdosing. The pivotal SURMOUNT trials studied the 2.5-15mg titration. Anecdotal patient reports describe meaningful effects at lower doses, but the evidence base is observational. Most clinicians reserve microdosing for patients who cannot tolerate standard doses or who have specific clinical reasons.
Lower doses generally produce fewer GI side effects (nausea, vomiting, diarrhea, constipation) but the formal safety profile of microdosing is uncharacterized. Risks not directly tied to dose — pancreatitis, gallbladder disease, contraindications, the labeled contraceptive interaction — apply at any dose. Always work with a prescriber who is monitoring you.
Without published trial data, defensible averages don't exist. Anecdotal reports vary widely. The dose-response relationship for tirzepatide is not linear at the lower end of the curve, and individual response varies. Patients seeking the predictable efficacy shown in SURMOUNT-1 should follow the standard titration schedule.
Common reasons: severe GI intolerance at standard doses, lower BMI patients, supply or cost constraints, post-discontinuation maintenance, or tolerability concerns from prior GLP-1 use. Microdosing tirzepatide is an off-label clinical decision that should be made jointly with a clinician who knows your full medical history.
There is no established or FDA-approved microdosing protocol, so there is no validated starting dose or schedule to follow - any dose below the approved 2.5 mg starting dose is off-label and has never been tested in a trial. If you and a qualified prescriber decide microdosing makes sense for cost or tolerability reasons, it should be started and adjusted under their supervision, ideally with a PCAB-accredited compounder and documented monitoring of your weight and symptoms so you can tell whether it is doing anything. The approved titration schedule exists precisely because that is the dosing that was actually studied for efficacy and safety, which is why many clinicians will still favor the lowest labeled dose over an unstudied fractional one. Do not self-select or self-start a microdose in isolation.

References

  1. 1.Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, Stefanski A; SURMOUNT-1 Investigators. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022. PMID: 35658024.
  2. 2.Frias JP, Davies MJ, Rosenstock J, Pérez Manghi FC, Fernández Landó L, Bergman BK, Liu B, Cui X, Brown K; SURPASS-2 Investigators. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). N Engl J Med. 2021. PMID: 34170647.
  3. 3.Coskun T, Sloop KW, Loghin C, Alsina-Fernandez J, Urva S, Bokvist KB, Cui X, Briere DA, Cabrera O, Roell WC, Kuchibhotla U, Moyers JS, Benson CT, Gimeno RE, D'Alessio DA, Haupt A. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Mol Metab. 2018. PMID: 30473097.
  4. 4.Eli Lilly and Company. ZEPBOUND (tirzepatide) injection — US Prescribing Information, Section 2.2 Important Administration Instructions and Section 2.3 Dosage Escalation. DailyMed (FDA Approved Labeling). 2025. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b
  5. 5.Eli Lilly and Company. MOUNJARO (tirzepatide) injection — US Prescribing Information. DailyMed (FDA Approved Labeling). 2025. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0
  6. 6.U.S. Food and Drug Administration. Off-Label Use of Approved Drugs and the Role of the Prescriber — FDA Basics for Patients. FDA Drug Information. 2023. https://www.fda.gov/patients/learn-about-expanded-access-and-other-treatment-options/understanding-unapproved-use-approved-drugs-label

Microdosing Ozempic and GLP-1s: What the Evidence Really Shows

Microdosing Ozempic, semaglutide, and tirzepatide explained: what low-dose GLP-1 use means, what the dose-response evidence supports, and the real risks.

10 min read

Life After GLP-1: Maintenance Dosing, Microdosing, Tapering & What Happens When You Stop (2026 Decision Hub)

After reaching goal weight on Wegovy, Zepbound, Mounjaro or Ozempic, you have four paths: stay on a maintenance dose, space doses further apart, microdose, or taper off. Each has different evidence and weight-regain expectations.

9 min read

GLP-1 Split Dosing: What the Evidence Actually Shows

Does splitting a weekly GLP-1 dose into smaller injections reduce nausea? What's actually been studied, what's pharmacologic extrapolation, and the safety issue that matters more than efficacy.

9 min read

How to Read Your Compounded GLP-1 Dose (Spot Errors)

Turn your compounded GLP-1 vial's mg/mL and syringe units into real milligrams, compare to normal FDA starting doses, and spot a dosing error before you inject.

9 min read

Zepbound Generic / Tirzepatide Biosimilar: When Will It Be Available? (2026 Status)

There is no FDA-approved generic Zepbound or tirzepatide in 2026, and Eli Lilly's core patents run into the mid-2030s. Why a generic is legally possible, and why compounded tirzepatide lost its FDA grace period in October 2024.

7 min read

Compounded GLP-1 Reconstitution Guide: Mixing Lyophilized Semaglutide and Tirzepatide Safely

A step-by-step FDA-cited guide to reconstituting lyophilized compounded semaglutide and tirzepatide with bacteriostatic water. Covers concentration math, vial handling, storage after reconstitution, and the common mistakes that ruin a vial or under-dose the patient.

9 min read

Where to get tirzepatide (Mounjaro / Zepbound) safely: vetted online providers

Vetted telehealth providers that prescribe online. We compare pricing, form, and states served.

No insurance needed · vetted by our editors

WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. How we make money

7.1

AgelessRx

Longevity-focused GLP-1 care with microdosing and brand-name options

Read full review →

From $209/mo (2-month plan rate)

Get started →
7.2

HumeCare+

GLP-1 weight loss with real-time body-composition tracking to protect muscle

Read full review →

From $299/mo

Get started →
8.3

Collective

The lowest flat medication price if you can absorb an annual membership fee

Read full review →

From $69/mo (+ required membership)

Get started →